Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients

Further Publications NeurologyFurther Publications Psychiatry

An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models

Lancet Neurol.

Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F

doi: 10.1016/S1474-4422(19)30244-3.

Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis

Neurology.

Scheibe F, Prüss H, Mengel AM, Kohler S, Nümann A, Köhnlein M, Ruprecht K, Alexander T, Hiepe F, Meisel A

doi: 10.1212/

Further Publications NeurologyFurther Publications Psychiatry

NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials

Neurology.

Thompson T, Whiter F, Gallop K, Veronese N, Solmi M, Newton P, Stubbs B

doi: 10.1212/WNL.

Parkinson’s DiseasePsychosis and Schizophrenia

High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.

J Clin Psychopharmacol.

Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN; Genetic Risk and Outcome of Psychosis (GROUP) Investigators

doi: 10.1097/

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Psychopharmacology (Berl).

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A

doi: 10.1007/s00213-016-4382-y

Psychosis and Schizophrenia

Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients

Int J Clin Pract.

Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T

doi: 10.1111/ijcp.12997.

RECOMMENDED

Anxiety and Depression

Psychotic features in patients with major depressive disorder: A report from the European Group for the Study of Resistant Depression

J Clin Psychiatry.

Dold M, Bartova L, Kautzky A, Porcelli S, Montgomery S, Zohar J, Mendlewicz J, Souery D, Serretti A, Kasper S

doi: 10.4088/JCP.17m12090.

Multiple Sclerosis

Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis patients

Cytometry B Clin Cytom.

Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A, Cano-Orgaz A, Mansilla MJ, Quirant-Sánchez B, Navarro-Barriuso J, Fernández-Sanmartín MA, Presas-Rodríguez S, Ramo-Tello C, Martínez-Cáceres EM

doi: 10.1002/cyto.b.21527.

Anxiety and DepressionPsychosis and Schizophrenia

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial

JAMA.

Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH, STOP-PD II Study Group.

doi: 10.1001/jama.2019.10517.

Related content